Ultragenyx Pharmaceutical (RARE) Current Leases (2019 - 2025)

Ultragenyx Pharmaceutical (RARE) has reported Current Leases for 7 consecutive years, with $12.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Current Leases rose 20.0% year-over-year to $12.0 million; the TTM figure through Dec 2025 stood at $12.0 million (up 20.0% YoY), while the FY2025 annual figure was $12.0 million, up 20.0% from the prior year.
• Current Leases fell to $12.0 million in Q4 2025 per RARE's latest filing, from $12.1 million in the prior quarter.
• Across five years, Current Leases topped out at $12.8 million in Q1 2024 and bottomed at $9.4 million in Q1 2021.
• Historically, Current Leases has averaged $11.3 million across 5 years, with a median of $11.5 million in 2022.
• Annual changes were most pronounced in 2021 — Current Leases jumped 37.42% — and 2024, when it declined 20.6%.
• Ultragenyx Pharmaceutical's Current Leases stood at $11.1 million in 2021, then grew by 6.44% to $11.8 million in 2022, then increased by 6.93% to $12.6 million in 2023, then slipped by 20.6% to $10.0 million in 2024, then rose by 20.0% to $12.0 million in 2025.
• Business Quant data shows RARE's Current Leases at $12.0 million in Q4 2025, $12.1 million in Q3 2025, and $11.8 million in Q2 2025.